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Abstract
Background: Tumor Necrosis Factor-a Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to
death receptor 4 and 5 are promising candidates for cancer therapy due to their ability to induce apoptosis
selectively in a variety of human cancer cells, while demonstrating little cytotoxicity in normal cells. Although TRAIL
and agonistic antibodies to DR4 and DR5 are considered safe and promising candidates in cancer therapy, many
malignant cells are resistant to DR-mediated, TRAIL-induced apoptosis. In the current work, we screened a small
library of fifty-five FDA and foreign-approved anti-neoplastic drugs in order to identify candidates that sensitized
resistant prostate and pancreatic cancer cells to TRAIL-induced apoptosis.
Methods: FDA-approved drugs were screened for their ability to sensitize TRAIL resistant prostate cancer cells to
TRAIL using an MTT assay for cell viability. Analysis of variance was used to identify drugs that exhibited synergy
with TRAIL. Drugs demonstrating the highest synergy were selected as leads and tested in different prostate and
pancreatic cancer cell lines, and one immortalized human pancreatic epithelial cell line. Sequential and
simultaneous dosing modalities were investigated and the annexin V/propidium iodide assay, in concert with
fluorescence microscopy, was employed to visualize cells undergoing apoptosis.
Results: Fourteen drugs were identified as having synergy with TRAIL, including those whose TRAIL sensitization
activities were previously unknown in either prostate or pancreatic cancer cells or both. Five leads were tested in
additional cancer cell lines of which, doxorubicin, mitoxantrone, and mithramycin demonstrated synergy in all lines.
In particular, mitoxantrone and mithramycin demonstrated significant synergy with TRAIL and led to reduction of
cancer cell viability at concentrations lower than 1 μM. At these low concentrations, mitoxantrone demonstrated
selectivity toward malignant cells over normal pancreatic epithelial cells.
Conclusions: The identification of a number of FDA-approved drugs as TRAIL sensitizers can expand
chemotherapeutic options for combination treatments in prostate and pancreatic cancer diseases.
Background
Tumor Necrosis Factor-a Related Apoptosis Inducing
Ligand (TRAIL) is a member of the Tumor Necrosis
Factor (TNF) super-family of cytokines that engages the
cellular apoptotic mechanism upon specific binding to
death receptors (DRs) 4 and 5 on the cell surface [1].
TRAIL has attracted significant attention in recent years
due to its ability to selectively induce apoptosis in trans-
formed (malignant) cells while demonstrating little
cytotoxicity in normal cells [2-7]. TRAIL binds cell-sur-
face death receptors (DR4 and DR5) as a homotrimer
and triggers the formation of the Death-Inducing Signal-
ing Complex (DISC); the Fas-Associated Death Domain
(FADD) and caspases 8 or 10 are recruited to the DISC
from the cytoplasm. The proteolytic activation of initia-
tor caspases leads to the subsequent activation of execu-
tioner caspases (e.g. caspase-3), which ultimately results
in apoptosis in Type I Cells. Activation of caspase-8
engages the mitochondria-amplified apoptosis machinery
in Type II cells [7]. The binding of TRAIL to decoy
receptors (DcR) 1 and 2 has also been demonstrated; it
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is hypothesized that these receptors play a role in main-
taining the homeostasis of TRAIL activity in vivo [2,8].
Recombinant TRAIL induces apoptosis in a variety of
human cancer cell lines including those of breast, colon,
lung, prostate, liver, leukemia, lymphoma, and neuro-
blastoma [4,6,8,9]. TRAIL has also demonstrated potent
anti-tumor activity in a number of xenograft models
including those of colon and breast carcinomas [10-12].
Soluble TRAIL variants are well tolerated in mice and
chimpanzees [13] and demonstrate minimal cytotoxicity
towards primary human hepatocytes and endothelial
cells in culture [7,14]. As a consequence of the selectiv-
ity towards malignant cells, certain TRAIL formulations
(e.g. non-histidine tagged TRAIL) are considered safe
for potential therapeutic applications [15].
Although TRAIL and agonistic antibodies to death
receptors 4 and 5 are promising candidates for cancer
therapy, many tumor cells are inherently resistant or
acquire resistance to TRAIL-mediated apoptosis. Com-
monly implicated resistance mechanisms include dys-
function of the Fas-Associated Death Domain (FADD)/
improper assembly of the Death-Inducing Signaling
Complex (DISC) [16], loss of caspase-8 activity [17-19],
constitutively active Akt/protein kinase B [20], and over-
expression of anti-apoptotic proteins such as c-Flip
[16,21] and Bcl-2 [22]. As a result, therapeutic strategies
involving DNA-damaging radiotherapy [23,24], genotox-
ins [25,26], and peptides [27] have been investigated for
enhancing cancer cell sensitivity to TRAIL [25] and/or
agonistic antibodies against DR4/DR5 [28].
Here, we report the parallel screening of fifty-five
FDA-approved and foreign-approved chemotherapeutic
drugs in order to identify existing anti-cancer drugs that
might act as TRAIL sensitizers in resistant prostate and
pancreatic cancer cells. Drugs were first pre-screened
individually (single agent treatment) for toxicity at a
concentration of 20 μM using TRAIL-resistant PC3-TR
prostate cancer cells; candidates that resulted in greater
than 70% reduction in cancer cell viability were screened
for TRAIL sensitization activity at a lower concentration
of 10 μM. A total of fourteen potential TRAIL sensitizer
leads, including six whose TRAIL sensitization activities
were previously unknown, were identified from the
screen. Five leads were further characterized in prostate
and pancreatic cancer cells.
Methods
Cell Culture
Two human prostate cancer cell lines (PC3, and PC3-
TR), three human pancreatic cancer lines (Panc-1, MIA-
PaCa2, and BXPC-3) and one immortalized human pan-
creatic epithelial cell line (HPDE6) were used in the
current study. PC3-TR (TR: TRAIL resistant) [29] cells
were a generous gift from Dr. Aria Olumi at the
Massachusetts General Hospital in Boston, MA. Cells
were grown in 75 cm2 Corning cell culture flasks with
RPMI 1640 tissue culture media supplemented with 10%
Fetal Bovine Serum and 1% penicillin/streptomycin
(10000 units/mL penicillin G and 10000 μg/mL strepto-
mycin) at 37°C with 5% CO2.
Reagent/Drug Preparation
The Johns Hopkins Chemical Compound Library (JHCCL)
[30] was purchased from The Johns Hopkins University
School of Medicine. The library contains a total of 1514
FDA- and foreign-approved drugs. The anti-neoplastic
plate (plate #1) consists of 55 FDA-approved approved
anti-cancer drugs and was employed in the screen for
identifying TRAIL sensitizers. All stock solutions of the
drugs from the library were supplied at a concentration of
10 mM in either DMSO or water. For expanded dose-
response experiments, additional doxorubicin and mitox-
antrone were purchased from Sigma while gemcitabine,
mithramycin, and thioTEPA were obtained through the
NCI/NIH Developmental Therapeutic Program. TRAIL
was purchased from R&D Systems and reconstituted in
PBS at a 10 μg/mL stock concentration in 50 μL aliquots
to prevent multiple freeze/thaw cycles. All solutions were
prepared to ensure that the final solvent (DMSO or water)
concentration in cell treatments would be less than 1% (v/
v) to limit non-specific activity.
Single Agent and Combination Treatments
Cells were plated in 96 well plates at a density of 8,400
cells/well and incubated at 37°C and 5% CO2 for
approximately 24 hours. For single-agent treatments,
cells were exposed to drug candidates at a concentration
of 20 μM for 24 hours at which point, cell viability was
determined using the MTT (3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide) assay (described
below). Single-agent TRAIL treatments were carried out
similarly; a dose range of 0-100 ng/mL of TRAIL was
used. For sequential combination treatments, cells were
first treated with a sensitizer drug candidate for 24
hours. The media was then removed, replaced with
fresh serum-containing media, and the cells were treated
with TRAIL. Cells were incubated for an additional 24 h
after which, viability measurements were carried out
using the MTT assay. In order to determine if dosing of
the combination treatment had an effect on the efficacy,
simultaneous combination treatments were carried out
by treating cells with the sensitizer drug and TRAIL at
the same time for 24 h at which point, cancer cell viabi-
lity was determined using the MTT assay.
Determination of Cell Viability
Cell viability was assessed using the MTT cell prolifera-
tion assay (ATCC CA#30-1010k). Following addition of
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the MTT reagent (2 h at 37°C), cells were treated with a
lysis buffer from the kit and kept at room temperature
in the dark for two hours in order to carry out complete
lysis and to solubilize the MTT product. The absor-
bance of each well was measured using a Biotech
Synergy 2 Multi-Detection Microplate Reader at 570
nm. Each experiment included a set of blank wells
(media only), a live control (no treatment) and a dead
control (200 μL of 10 μM H2O2 or 1.5 μL of 20 μM
Quillaja were employed for inducing death in the cell
population). Background absorbance was measured
using the blank and subtracted from all absorbance
measurements. In the case of drugs that potentially
interfered with the assay, a separate set of media-only
wells were treated with equivalent volumes of the drug,
and the measured absorbance was subtracted as the
background. This was carried out to eliminate any bias
caused by the natural absorbance of the drug itself.
Fractional cell viability was calculated as: (OD of sample
- OD of dead control)/(OD of live control - OD of dead
control) where OD is the optical density. Percentage cell
viability was calculated by multiplying the fractional via-
bility by 100. Data are plotted as percentage reduction
in cell viability compared to control (untreated cells) in
which, a 0% value on the graph means 100% viability
and 100% value on the graph means 0% viability.
Statistical Analyses
Screening experiments were carried out in duplicate and
expanded dose responses with identified leads were per-
formed at least in triplicate. Data are presented as the
mean ± one standard deviation. The standard deviation
of each set was calculated based on the variation
between experiments. ANOVA was performed using the
t-test function in Microsoft Excel. Analysis of the single-
agent treatment was performed in order to determine
whether or not a drug had a significant effect when
compared to the live (untreated) control. Efficacies of
sensitization were determined by comparing the
decrease in cell viability following combination treat-
ments (i.e. drug in combination with TRAIL) to the
reduction in cell viability as a consequence of the addi-
tive effect of single-agent treatments (drug alone + 10
ng/mL TRAIL alone).
Live/Dead Analysis
As an alternate assessment of cell viability, a calcein
AM/ethidium homodimer-1 (EthD-1) viability/cytotoxi-
city kit (Invitrogen L3224) was used to measure treat-
ment efficacy for a select set of combination treatments.
Briefly, a working solution of 2 μM calcien AM and 4
μM ethidium homodimer-1 (EthD-1) was prepared in a
solution of sterile 1× PBS. The working solution was
then added to each well of the cell culture plate and
incubated at 37°C with 5% CO2 for 30-45 minutes.
Fluorescence imaging was then carried out using a Zeiss
Observer D1 fluorescent microscope. A 38 HE filter set
(Excitation: 470/40; Emission: 525/50) was used to
image the fluorescence of the calcein AM (green fluor-
escence) while a 43 HE filter set (Excitation: 550/25;
Emission: 605/70) was used to measure the fluorescence
of the EthD-1 (red fluorescence).
Annexin V and Propidium Iodide Analysis
An annexin V/propidium iodide assay (Invitrogen
L3224) was carried out to determine if combination
treatments induced apoptosis in cells. Briefly, a working
solution of 2% annexin V and 1 μg/mL propidium
iodide (PI) was prepared in a solution of 1× annexin
binding buffer. The working solution was added to each
well of the cell culture plate and incubated at room
temperature for 15-20 minutes. Fluorescence imaging
was then performed using a Zeiss Observer D1 fluores-
cent microscope. A 38 HE filter set (Excitation: 470/40;
Emission: 525/50) was used to measure the fluorescence
of the annexin V (green fluorescence) while a 43 HE fil-
ter set (Excitation: 550/25; Emission: 605/70) was used
to measure the fluorescence of the propidium iodide
(red fluorescence).
Image Analysis
All image processing was performed using ImageJ [31]
image processing software. For the live/dead analysis the
threshold of the fluorescent image was adjusted so that
any background noise was removed and that the bound-
ary between individual cells was well defined. The image
was then converted to a binary format. In some cases, it
was difficult to differentiate between cell boundaries in
which case the Watershed process was used to distin-
guish between individual cells while ensuring that any
cells that were incorrectly divided were accounted for
[32]. The “Analyze Particles” function was then used to
obtain a final cell count. The live cell count was then
normalized against the live control cell count to give an
indication of the cell viability. The brightness of the
images was adjusted so that the background had zero
pixel intensity value in case of annexin V/PI analyses.
Next, false color was applied to the image; green was
applied for the annexin V stains and red was applied to
the PI stains.
Results and discussion
In the current study, we screened a small library of fifty-
five FDA- and foreign-approved antineoplastic drugs
from the Johns Hopkins Clinical Compound Library
(JHCCL) in order to identify chemotherapeutics that
sensitize prostate and pancreatic cancer cells to TRAIL-
induced apoptosis. Identification of FDA-approved drugs
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as TRAIL sensitizers is an attractive discovery strategy
since it is possible to rapidly translate these novel com-
binations to the clinic. PC3-TR (TR: TRAIL resistant)
human prostate cancer cells were used in the primary
screening, since it was hypothesized that lead candidates
discovered for this resistant cell line might be relevant
to clinical phenotypes that develop resistance to TRAIL.
The cell line demonstrated low susceptibility to single-
agent TRAIL treatments; a 20% loss of viability reduc-
tion was observed in PC3-TR cells at concentrations as
high as 100 ng/mL (Additional File 1). We employed a
TRAIL concentration of 10 ng/mL in subsequent com-
bination treatment experiments in order to keep the
TRAIL dose at a minimum; under these conditions, sin-
gle-agent TRAIL induced a loss of viability in approxi-
mately 4% of the PC3-TR cell population. To our
knowledge, these are the first screening experiments
carried out with the PC3-TR TRAIL-resistant prostate
cancer cell line.
Identification of FDA-Approved Drugs as TRAIL Sensitizers
in Prostate and Pancreatic Cancer Cell Lines using Parallel
Screening
The overall screening schematic is shown in Additional
File 2. PC3-TR cells were initially treated with 20 μM of
each drug in order to carry out an initial screen for drug
toxicity. Eleven drugs (arsenic, daunorubicin, doxorubicin,
epirubicin, fludarabine, idarubicin, irinotecan, docetaxel,
mithramycin, gold, mitoxantrone) resulted in > 30% loss
in PC3-TR cell viability at 20 μM in the initial toxicity
screen (Additional File 3) and were screened for their
TRAIL sensitization activities at a lower concentration of
10 μM (Figure 1). Use of lower drug concentrations (10
μM) limits the single agent toxicity, which can also allow
for identification of synergistic interactions with TRAIL.
Forty-four drugs from the library demonstrated cell viabil-
ities higher than 70% at a concentration of 20 μM and
were screened for their ability to sensitize PC3-TR cells to
TRAIL under these conditions (Figure 2).
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Figure 1 Parallel screening of drugs from the Johns Hopkins Chemical Compound Library as TRAIL sensitizers. PC3-TR human prostate
cancer cells were first incubated with drug treatments (10 μM) for 24 hours after which time the media was removed, refreshed and cells were
treated with TRAIL (10 ng/mL) for an additional 24 hrs.
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Combination treatments with sensitizer drugs (24 h)
followed by TRAIL (24 h) were carried out in a
sequential treatment format to identify candidates that
sensitized PC3-TR cells to TRAIL-induced apoptosis.
Combination treatments that induced statistically sig-
nificant (p < 0.05) reduction in the viability of PC3-TR
cells, compared to the sum of the individual treatments
(i.e. additive effects of TRAIL alone + chemosensitizer
drug alone), were identified as leads. Nine drugs, dau-
norubicn, doxorubicin, fludarabine, idarubicin, irinote-
can, docetaxel, mithramycin, mitoxantrone and
epirubicin, were identified as lead sensitizers of
TRAIL-induced apoptosis from the 10 μM screen (Fig-
ure 1). Of these, seven have been previously identified
as TRAIL sensitizers for different malignancies, but
only five have been reported for prostate cancer (Table
1) [33-37]. To our knowledge, two drugs, idarubicin
and mitoxantrone, have not been previously described
as TRAIL sensitizers for any cancer cell type and are
therefore new candidates that can be used in combina-
tion with TRAIL. The screen with 20 μM drug concen-
tration identified the following drugs as TRAIL
sensitizer leads: cladribine, cytarabine, gemcitabine,
thioguanine and thioTEPA (Figure 2). Of these drugs,
gemcitabine has been previously shown as a TRAIL
sensitizer in different malignant cells, including pros-
tate and pancreatic cancers [26]. Taken together, the
two screens led to the identification of fourteen che-
motherapeutic drug leads that sensitize PC3-TR pros-
tate cancer cells to TRAIL-induced apoptosis; other
candidates that demonstrated moderate efficacies (for
example, toremifene, lomustine, temozolomide, amino-
glutethimide, and letrozole) were also identified but
not pursued further due to the presence of more pro-
mising leads. These results indicate that the screen
accurately identified both, existing as well as new
TRAIL sensitizers from the drug library. A summary of
effective TRAIL sensitizers from the screen, along with
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Figure 2 Parallel screening of drugs from the Johns Hopkins Chemical Compound Library (JHCCL) as TRAIL sensitizers. PC3-TR cells
were first incubated with drug treatments (20 μM) for 24 hours after which time the media was removed, refreshed and cells were treated with
TRAIL (10 ng/mL) for an additional 24 hrs.
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their corresponding efficacies for reducing cancer cell
viability, is provided in Table 1.
From the TRAIL chemosensitizer leads identified
above, five drugs - doxorubicin, gemcitabine, mithramy-
cin, mitoxantrone, and thioTEPA were chosen for addi-
tional evaluation. These drugs have been approved by
the FDA for chemotherapeutic administration in differ-
ent malignancies. Doxorubicin and gemcitabine were
selected since both have been previously characterized
as TRAIL-sensitizing agents in prostate and/or pancrea-
tic cancer cells [21,38-41]. Mithramycin has also been
shown to sensitize prostate cancer cells to TRAIL [37]
but to our knowledge, the drug has not been previously
demonstrated to possess TRAIL sensitization activity in
pancreatic cancer cells. Neither mitoxantrone nor thio-
TEPA has previously been shown to act as TRAIL sensi-
tizers in cancer cells to the best of our knowledge.
Additional factors that were used to determine candi-
dates for subsequent characterization included single-
agent drug toxicities in the PC3-TR cell line (drugs with
lower toxicities were given preference), the total loss of
cancer cell viability induced by the combination treat-
ment compared to the single agent treatments, and
prior knowledge of the drugs as TRAIL sensitizers.
Additional evaluation involved expanding the range of
the drug dose from 0 to 20 μM for doxorubicin and 0
to 100 μM for the other drugs in PC3-TR and PC3
human prostate cancer cells, and the Panc-1 human
pancreatic cell cancer line. It is important to note that
the screening experiments employed drugs from the
JHCCL (frozen 10 mM aliquots), while the lead charac-
terization experiments employed drugs obtained from
Sigma (doxorubicin, mitoxantrone) and the NCI/NIH
Developmental Therapeutic Program (gemcitabine,
mithramycin, thioTEPA) which were reconstituted in
either DMSO or water, based on the solvent that was
used for the respective drugs supplied in the JHCCL.
Combination treatments were carried out with 10 ng/
mL TRAIL, which induced a loss of viability of 4.3%
(+/- 3.2%) in PC3-TR cells, 8.4% (+/- 4.2%) in PC3 cells,
and 1.4% (+/- 7.4%) in Panc-1 cells, when administered
alone. Such low levels of viability loss are demonstrative
of the resistance of these cancer cells to TRAIL-induced
apoptosis. It is important to note that while PC3-TR
cells are derived from PC3 cells, the two lines are inher-
ently different and therefore, it can be expected that the
two cell lines respond differently to drug treatments.
For example, we have previously shown that closely
related prostate cancer cell lines, PC3 and PC3-PSMA
cells, demonstrate markedly different behavior in
response to nanoparticle treatment [42].
The expanded dose range of the lead candidates in the
PC3-TR cell line showed trends similar to those seen in
the primary screen; all lead candidates induced signifi-
cant losses in cancer cell viability when used in combi-
nation with TRAIL (Figure 3, Figure 4, Figure 5,
Additional File 4, Additional File 5). Doxorubicin,
mithramycin, and mitoxantrone demonstrated synergis-
tic efficacies in combination with TRAIL in PC3 and
Panc-1 cells (Figure 3, Figure 4, Figure 5). Conversely,
Table 1 Summary of drugs identified as TRAIL sensitizing agents and their previously known activity.
10 μM
Drug Name Drug
Alone
Drug Alone +
TRAIL Alone
(Additive)
Combination
Treatment
p-Value Known TRAIL
Sensitizer?
Known TRAIL Sensitizer
in Prostate Cancer?
Known TRAIL Sensitizer in
Pancreatic Cancer?
Daunorubicin 47 51.3 95.6 < 0.01 Yes No No
Docetaxel 31.2 35.5 72.7 < 0.01 Yes Yes No
Doxorubicin 39 43.3 90.8 < 0.01 Yes Yes Yes
Epirubicin 34.7 39 58.7 < 0.05 Yes Yes No
Fludarabine 58.6 62.9 86.2 < 0.05 Yes No No
Idarubicin 53.3 57.6 97.7 < 0.01 No No No
Irinotecan 30.6 34.9 65.4 < 0.01 Yes Yes No
Mithramycin 28.6 32.9 95 < 0.01 Yes Yes No
Mitoxantrone 52.2 56.5 97.7 < 0.01 No No No
20 μM
Cladribine 0 4.1 38.5 < 0.05 No No No
Cytarabine 7.9 12.2 32.9 < 0.05 No No No
Gemcitabine 28.4 32.7 70.5 < 0.01 Yes Yes Yes
Thioguanine 4.7 9 40.8 < 0.05 No No No
Thiotepa 6.2 10.5 47.2 < 0.01 No No No
Values are listed as mean percent viability reduction. Leads employed in an expanded dose response are shown in bold font.
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neither gemcitabine nor thioTEPA demonstrated signifi-
cant synergy in these cells (Additional File 4, Additional
File 5).
The median concentrations of single-agent doxorubi-
cin (Figure 3) that resulted in 50% loss of viability in the
cancer cell population compared to the untreated con-
trol (LC50) were approximately 0.6 μM, 6 μM and 0.6
μM in PC3-TR, PC3, and Panc-1 cells, respectively.
However, in combination with 10 ng/mL TRAIL, the
LC50 values for doxorubicin were 0.25 μM for PC3-TR
and PC3 cells, and 0.1 μM (100 nM) for Panc-1 cells, all
of which are substantially lower than the single-agent
concentrations (Figure 3). The greatest loss of cancer
cell viability for the doxorubicin-TRAIL combination
treatment compared to single-agent doxorubicin treat-
ment was observed at 0.33 μM (42%), 1 μM (44.4%),
and 0.33 μM (55%) for PC3-TR, PC3, and Panc-1 cells,
respectively (Figure 3). The cytotoxic effect of doxorubi-
cin is attributed to its DNA intercalation as well as its
disruption of cellular functions upon cell membrane
binding. Intercalation inhibits nucleotide replication via
the stabilization of type II topoisomerase [43]. Doxoru-
bicin is currently approved for the treatment of acute
lymphoblastic leukemia, acute myeloblastic leukemia,
Wilms’ tumor, neuroblastoma, soft tissue and bone sar-
comas, breast cancer, ovarian cancer, transitional cell
bladder cancer, thyroid cancer, gastric cancer, Hodgkin’s
disease, malignant lymphoma, bronchogenic cancer,
ovarian cancer, AIDS-Related Kaposi’s sarcoma, and
multiple myeloma. The TRAIL sensitization activities of
doxorubicin are due to the ability of the drug to down-
regulate the anti-apoptotic protein c-FLIP [38,44], acti-
vate pro-apoptotic caspases [45,46] and induce reactive
oxygen species (ROS) formation in cancer cells [47].
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Figure 3 Dose response for doxorubicin in malignant cell lines. (a) PC3-TR, (b) PC3 human prostate cancer cells, and (c) Panc-1 pancreatic
cancer cells. Single-agent treatments are shown as “dark grey diamonds” and combination treatments with 10 ng/mL of TRAIL are shown as
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the concentrations at which the enhancement in viability reduction is the greatest. Data are presented on a logarithmic scale and the lines
connecting data points are for visualization only.
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Thus, the genotoxic activity of doxorubicin activates the
internal apoptosis pathway, while simultaneously sensi-
tizing the cell to external, receptor-mediated apoptosis
by the TRAIL ligand.
The LC50 values for single-agent mithramycin were 20
μM, 0.5 μM and 6 μM for PC3-TR, PC3, and Panc-1
respectively. However, in combination with 10 ng/mL
TRAIL, the LC50 values for mithramycin were approxi-
mately 0.2 μM for PC3-TR and PC3 cells, and 0.1 μM
for Panc-1 cells, respectively (Figure 4). Combination
treatments with mithramycin (plicamycin) demonstrated
the greatest enhancement in loss of cancer cell viability
at 6.6 μM (50.5%), 0.66 μM (24.9%) and 0.33 μM
(48.6%) in PC3-TR, PC3, and Panc-1 cells respectively,
compared to single-agent mithramycin treatment (Figure
4). Importantly, mithramycin demonstrated one of the
highest efficacies in combination with TRAIL; a differ-
ence of 67% in loss of cancer cell viability was seen for
the combination treatment compared to the additive
effect of the single-agent treatments (67% increase; Fig-
ure 1). Mithramycin is an antineoplastic antibiotic
derived from Streptomyces and is approved by the FDA
for the treatment of testicular cancer and hypercalcae-
mia [48]. The antineoplastic properties of mithramycin
are likely linked to the binding of mithramycin to GC-
rich section of DNA and the subsequent inhibition of
RNA synthesis and regulation of transcription [49]. The
TRAIL-sensitization activity of mithramycin is not very
well characterized, but one study suggests that this
activity is caused by the down regulation of X-linked
Inhibitor of Apoptosis Protein (XIAP) [37]. XIAP inhi-
bits apoptosis by binding to and inhibiting caspases 3, 7
and 9. Mithramycin is able to prevent the transcription
of XIAP through its binding activity to DNA [37,48].
This action would sensitize cancer cells to both, intrinsic
and extrinsic apoptosis pathways. However, the extent
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to which mithramycin activated the intrinsic pathway
has not been elucidated.
LC50 values for single-agent mitoxantrone were
approximately 10 μM for PC3-TR and PC3 cells, and 5
μM for Panc-1 cells. However, in combination with 10
ng/mL TRAIL, the LC50 values for mitoxantrone were
significantly reduced to 0.6 μM, 0.1 μM and 1 μM for
PC3-TR, PC3 and Panc-1 cells, respectively (Figure 5).
In the case of mitoxantrone-TRAIL combination treat-
ment, the greatest enhancement in loss of viability was
observed at 6.6 μM (55.0%) in PC3-TR, 0.33 μM (60.8%)
in PC3, and 6.6 μM (38.5%) in Panc-1 cells (Figure 5),
compared to mitoxantrone alone. The chemotherapeutic
activity of mitoxantrone is attributed to its ability to
intercalate into DNA, resulting in cross-links and strand
breaks. Additionally, mitoxantrone also interferes with
RNA synthesis and inhibits topoisomerase II [50].
Mitoxantrone has been approved by the FDA for pallia-
tive treatment of prostate cancer and curative treatment
of acute nonlymphocytic leukemia; the drug has also
been recently approved for the treatment of multiple
sclerosis. Although we did not find reports that describe
the use of mitoxantrone as a TRAIL sensitizer, mitoxan-
trone has been demonstrated to possess synergistic rela-
tionship with Tumor Necrosis Factor (TNF) for
inducing apoptosis in cells [51,52]. A detailed evaluation
that describes the mechanisms behind the TRAIL-sensi-
tization activity of mitoxantrone is currently under
investigation in our laboratory.
In the case of gemcitabine, statistically significant
enhancement of viability reduction occurred in PC3-TR
at concentrations above 6.6 μM (Additional File 4).
Further increase in concentration to 100 μM resulted in
an enhancement of cell viability loss up to a maximal
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value of 29% for the combination treatment over the
single drug treatment. Gemcitabine is currently
approved for the treatment of ovarian cancer (with car-
boplatin), breast cancer (with paclitaxel), non-small cell
lung cancer (with cisplatin), and pancreatic cancer.
Gemcitabine is metabolized intercellularly to active
diphosphate and triphosphate nucleosides which work
via two mechanisms to inhibit DNA synthesis. First,
gemcitabine diphosphate inhibits the enzyme ribonu-
cleotide reductase, which is a catalyst of reactions to
form deoxynecleoside triphosphates. Second, gemcita-
bine triphosphate competes with other deoxynecleoside
triphosphates for incorporation into DNA, which is
enhanced by the action of gemcitabine diphosphate.
Although the TRAIL sensitization activity of gemcita-
bine is not fully understood, it is hypothesized that the
response is related to the activation of pro-apoptotic
caspases [26,41]. Previous results have shown that the
combination treatment of gemcitabine and TRAIL
increases the activation of caspases 8 and 3, while a sin-
gle agent treatment of gemcitabine increases the activa-
tion of only caspase 3 [41]. Although synergy was
observed in PC3-TR cells with gemcitabine, we did not
see synergy between gemcitabine and TRAIL in PC3
and Panc-1 cells, which differs from other reports in the
literature [26,41]. This is likely due to differences in the
concentrations of both drug and TRAIL conditions that
were employed in these other studies; for example,
other studies have employed 100 ng/mL TRAIL, which
is ten-fold higher than the concentration used in our
study [26,41].
ThioTEPA has been approved by the FDA for the
treatment of breast cancer, ovarian cancer, superficial
papillary carcinoma of urinary bladder, lymphosarcoma,
and Hodgkin’s disease. ThioTEPA is a radiomimetic
drug that can produce ethylenimine radicals, which
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disrupt DNA. ThioTEPA showed a 40% difference in
viability reduction between the combination treatments
and the additive effect of the single agent treatments in
the initial screen with PC3-TR; however, only an 8%
increase was observed in case of the combination treat-
ment compared to individual treatments in the subse-
quent experiments (Figure 2 & Additional File 5). This
might be due to the different sources of the drug
employed in the screening and characterization
experiments.
In order to confirm the above results obtained using
the MTT assay, a secondary analysis method using Live/
Dead® fluorescence staining was employed to count liv-
ing cell populations following single agent mitoxan-
trone/mithramycin treatments as well as TRAIL-based
combination treatments in the PC3-TR cell line. Image
analysis showed that single agent TRAIL caused a 6%
(+/- 4%) decrease in cell viability (not shown). Figure 6
compares cell viability calculated using the MTT assay
to the normalized live cell count. The greatest deviation
between the MTT and live/dead analysis occurs in the
combination mitoxantrone and TRAIL experiments.
Deviation is greatest at lower concentrations of mitox-
antrone but diminishes as the concentration increases.
The average difference between cell viability data for
single agent mitoxantrone is 12.9% between the two
methods, while the average difference is 15% for the
mitoxantrone-TRAIL combinations. The single-agent
and combination treatments with mithramycin show
excellent agreement between the two cell viability analy-
sis methods. The average difference between analysis
methods is 10.4% for mithramycin alone and only 5.6%
for the mithramycin-TRAIL combination treatment.
These results indicate that the MTT and the live/dead
methods are comparable for these systems, which is an
indication that the MTT assay is a reliable method for
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screening and rapidly identifying synergistic combina-
tion treatments.
Following the identification of mitoxatrone and
mithramycin as potent sensitizers of TRAIL-induced
apoptosis in cancer cells above, we further evaluated the
activities of these drugs in two additional human pan-
creatic cancer cell lines, BXPC-3 and MIAPaCa2 (Figure
7). Single-agent TRAIL treatments resulted in a loss of
viability in 14.3% (+/- 9.8%) in BXPC-3, and 9.2%
(+/-3.8%) in MIAPaCa2 cells. The LC50 value for single-
agent mitoxantrone was approximately 4 μM for BXPC-
3 and 3 μM for MIAPaCa2 cells. In comparison, the
LC50 values for the mitoxantrone-TRAIL combination
treatments were 0.66 μM for BXPC-3 and 0.1 μM for
MIAPaCa2 cells. Similarly, LC50 values for single-agent
mithramycin were 0.3 μM for BXPC-3 and 0.2 μM for
MIAPaCa2 cells. The LC50 values for the mithramycin-
TRAIL combination treatments were less than 0.1 μM
(100 nM) for both, BXPC-3 and MIAPaCa2 cells. In
BXPC-3 cells, the largest difference in loss of viability
induced by the drug-TRAIL combination compared to
single-agent drug treatment were observed at 6.6 μM
(18.5%) and 0.33 μM (42.0%) for mitoxantrone and
mithramycin, respectively. In MIAPaCa2 cells, the lar-
gest enhancements in viability reduction following com-
bination treatments were observed with mitoxantrone
and mithramycin doses of 0.33 μM (37.5%) and 33.3 μM
(28.0%), respectively. In case of mitoxantrone, the
TRAIL sensitization activity was most effective at lower
concentrations of the drug; extensive reduction in can-
cer cell viability was observed with high concentrations
of mitoxatrone in these cells. In contrast, the response
was largely invariant as a function of concentration for
mithramycin in these cells. These results are similar to
those observed with other cancer cell lines (Figure 4,
Figure 5). Taken together, the significant reduction in
the LC50 values observed in case of combination treat-
ments, compared to the additive effects of single-agent
treatments of chemotherapeutic drugs and TRAIL,
further demonstrates the efficacy this approach for the
ablation of pancreatic cancer cells.
The Combination Treatment of Low-dose Mitoxantrone
and TRAIL is Selective towards Malignant Pancreatic Cells
Compared to Normal Pancreatic Epithelial Cells
With the exception of gemcitabine and thioTEPA, the
largest enhancements in viability reduction occurred at
sub-micromolar or low micromolar concentrations for
the other drugs. This is significant since the use of
lower concentrations of these genotoxins can reduce
damage to healthy tissue during therapy. This was
demonstrated further by comparing single-agent verses
the combination treatment LC50 values for each of the
chemotherapeutic drugs. In the case of doxorubicin,
mithramycin and mitoxantrone, the LC50 values
decreased when each of these drugs was used in combi-
nation with TRAIL regardless of the cell line. With dox-
orubicin, this decrease in the LC50 value was relatively
small in PC3-TR (0.6 μM to 0.25 μM) and Panc-1 (0.6
μM to 0.1 μM) cells, but significant in PC3 cells (6 μM
to 0.25 μM). Mithramycin exhibited a relatively small
change in the LC50 value for PC3 cells (0.5 μM to 0.2
μM), a moderate change for Panc-1 cells (6 μM to 0.1
μM), and the largest total change for PC3-TR cells (20
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“light grey squares”. Data are presented on a logarithmic scale and the lines connecting data points are for visualization only.
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μM to 0.2 μM). Mitoxantrone demonstrated a moderate
decrease in the LC50 value for Panc-1 cells (5 μM to 1
μM) and significantly larger decreases in LC50 values for
the drug in combination with TRAIL in both, PC3-TR
(10 μM to 0.6 μM) and PC3 (10 μM to 0.1 μM) cells.
We tested the effects of mitoxantrone and mithramy-
cin in the non-malignant HPDE6 [53,54] pancreatic cells
in order to determine the selectivity of these two drugs
and their combination with TRAIL for malignant cells
compared to normal cells (Figure 8). Single agent
TRAIL showed a viability loss of 3.3% (+/- 12.4%) in
HDPE6 cells compared to untreated cell control,
suggesting that TRAIL shows little to no activity in
these cells. Low concentrations (0.33 and 0.6 μM) of
single-agent mitoxantrone also exhibited minimal loss in
HPDE6 cell viability, while the 20 μM treatment
resulted in a loss of viability of approximately 50% cells.
Single agent mithramycin treatment, however, resulted
in a loss of viability in 40%-60% of the cell population
even at the lower concentrations, which was consider-
ably higher than that observed with mitoxantrone (Fig-
ure 8). A comparison of the single agent treatments and
the combination treatments for mitoxantrone indicated
selectivity of the drug at lower concentrations. In HDPE
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cells, 0.33 and 0.6 μM mitoxantrone in combination
with 10 ng/mL TRAIL induced a 13.9% (+/- 4.5%) and
19.8% (+/-6.6%) loss of viability respectively, while
mitoxantrone alone resulted in 19.3% (+/- 9.2%) and
18.4% (4.1%) at these doses. Importantly, single agent
mitoxantrone and mitoxantrone + TRAIL induced a
respective loss of cell viability of 16% and 28.4% in
Panc-1 cells, 10.6% and 40% in BXPC3 cells, 23.4% and
70% in MIAPaCa2 (0.33 μM mitoxantrone). These con-
ditions indicate that the combination of low-dose mitox-
antrone with TRAIL is selective towards malignant
pancreatic cells compared to normal cells. As may be
expected, this selectivity is lost at higher concentrations
of mitoxantrone. We did not observe significant selectiv-
ity for cancer cells compared to non-malignant cells in
case of mithramycin. While the results with mitoxan-
trone are promising due to the observed selectivity, an
effective chemotherapeutic window of operation may be
available for the mithramycin-TRAIL combination in
vivo.
Higher Concentrations of TRAIL in Combination
Treatments do not Demonstrate Increased Efficacies
The previous studies were carried out with different
concentrations of the chemosensitizer drug followed by
a single dose of TRAIL (Additional File 1). Following
identification of mitoxantrone and mithramycin as
potential TRAIL sensitizers, we investigated the effect of
different TRAIL concentrations in combination with a
single dose of these sensitizer drugs. LC50 values for
mitoxantrone-TRAIL and mithramycin-TRAIL combina-
tion treatments were 0.6 and 0.2 μM, respectively, for
PC3-TR cells. The single-agent 0.6 μM mitoxantrone
treatment, resulted in a loss of viability of 31.4% (+/-
2.0%) in PC3-TR cells compared to the untreated con-
trol (Figure 9), which is in good agreement with the
data trend shown in Figure 5. The single agent treat-
ment of 0.2 μM mithramycin resulted in a loss of viabi-
lity of 18.9% (+/- 2.1%) of cells compared to untreated
cells (Figure 9), which is also in good agreement with
data shown in Figure 4. As expected, the loss of cancer
cell viability upon treatment with single-agent 0.6 μM
mitoxantrone and 0.2 μM mithramycin was less than
50%, since these are less efficacious than the combina-
tion treatments. These single-agent concentrations were
chosen to investigate the efficacy of different TRAIL
doses, which were varied from 0-100 ng/mL (Figure 9).
Over the concentration range studied for TRAIL, the
overall reduction in cell viability between the lowest (0.5
ng/mL) and highest (100 ng/mL) TRAIL concentrations
increases by only 10% for both drug treatments, indicat-
ing that lower TRAIL doses (e.g. 10 ng/mL) may possess
sufficient activity in the current combination treatments.
Sequential vs. Simultaneous Combination Treatments
In the previous experiments, combination treatments
were performed in a sequential format by first treating
cells with a sensitizing drug for 24 hours, removing
the drug from the cells, and then applying a TRAIL
treatment for an additional 24 hours. An alternate
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Figure 10 Comparison between different treatment methodologies in PC3-TR cells. (a) Mitoxantrone (b) and mithramycin in PC3-TR
prostate cancer cells. Single-agent treatments are shown as “dark grey diamonds”, sequential combination treatments with 10 ng/mL of TRAIL
are shown as “light grey squares” and simultaneous combination treatments with 10 ng/mL of TRAIL are shown as “grey triangles”. Data are
presented on a logarithmic scale and the lines connecting data points are for visualization only.
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combination treatment methodology is to apply both
the sensitizing drug and TRAIL “simultaneously” in
which both, the drug and TRAIL are administered
together. In our hands, simultaneous treatments with
mitoxantrone demonstrated a higher loss of PC3-TR
cell viability for low concentrations of the drug
compared to the sequential treatments (Figure 10).
However, this trend is reversed at higher drug
concentrations.
The overall increase in loss of cancer cell viability
between the lowest concentration of mitoxantrone (0.33
μM) and the highest concentration of mitoxantrone
Figure 11 Microscopy images of mitoxantrone treated PC3-TR cells. Left panels are phase contrast images and right panels are fluorescence
images visualized with an annexin V and propidium iodide stain. Apoptotic cells exhibit green fluorescence only. Dead cells can exhibit either
lone red fluorescence or red and green fluorescence simultaneously. Live cells are non-fluorescent. Arrows identify apoptotic cells.
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(100 μM) for the simultaneous treatments is about 25%
(Figure 10), compared to 65% for sequential treatments.
Interestingly, mithramycin did not show large differ-
ences in the loss of cell viability between the sequential
and the simultaneous combination treatments. The dif-
ference between the two drugs and their dependence on
treatment order is likely most closely related to the
kinetics of how each drug is processed and how quickly
the sensitization effect is achieved. In the case of
mithramycin it is likely that the kinetics of sensitization
are rapid and that even when the drugs are co-adminis-
tered, there is sufficient time for the drug to sensitize
the cells to TRAIL mediated apoptosis. On the other
hand, it is possible that the kinetics of sensitization are
slower for mitoxantrone and that the synergy between
mitoxantrone and TRAIL is highest when the drug has
sufficient time to overcome cellular resistances to
TRAIL. We are currently following up on these observa-
tions in our laboratory.
Mitoxantrone-TRAIL and Mithramycin-TRAIL Combinations
induce Apoptosis in PC3-TR Cells
In order to verify the induction of apoptosis, cells were
treated with an annexin V and propidium iodide (PI)
stain following incubation with single-agent and combi-
nation drug treatment. The annexin V/PI stain distin-
guishes between apoptotic and necrotic cells based on
fluorescence. In this assay, live cells will not fluoresce,
early apoptotic cells fluoresce green, while late apoptotic
and necrotic cells can fluoresce either red or demon-
strate both red and green fluorescence. Images were
acquired for single agent and combination treatments of
mitoxantrone (Figure 11) and mithramycin (Additional
File 6) in PC3-TR cells. As expected, the live cell control
and the 10 ng/mL TRAIL-alone treatment control
demonstrated little to no fluorescence. Single agent
treatment with mitoxantrone (0.33 μM) resulted in both
apoptotic and necrotic cell populations, although the
majority of the cell population consisted of live cells.
The corresponding mitoxantrone-TRAIL simultaneous
combination treatment results in a large population of
apoptotic and necrotic cells (Figure 11), which also
demonstrate changes in cell. Mithramycin treatments
demonstrated similar trends and showed a clear
decrease in cell population between single agent and
combination treatments. This validates results shown in
Figure 4. Overall, these results indicate that TRAIL-
based combination treatments with mitoxantrone and
mithramycin induce apoptosis in PC3-TR cells.
Conclusions
In the current study, fifty-five FDA- and foreign-
approved antineoplastic drugs were screened in order to
identify chemotherapeutic candidates that sensitized
malignant prostate and pancreatic cells to TRAIL-
induced apoptosis. The initial screen was performed
using a TRAIL resistant prostate cancer cell line (PC3-
TR) and several drugs were identified as potential sensi-
tizing agents. The screen was able to identify drugs with
previously unknown TRAIL sensitization activities in
prostate as well as pancreatic cancer cells, which can
lead to the identification of new chemotherapeutic drug
combinations and therefore potentially increase thera-
peutic options against these malignancies. Future work
will involve expansion of the screen to other drug candi-
dates, a detailed investigation into the mechanisms
responsible for the sensitization activities of the leads
and an evaluation of their efficacy in relevant animal
models of prostate and pancreatic tumors.
Additional material
Additional file 1: Dose response for TRAIL as a single agent
treatment in the PC3-TR cell line. Cells were incubated with TRAIL for
a 24-hour period followed by analysis with MTT. TRAIL at 10 ng/mL
concentration causes a 4.3% (+/- 3.2%) increase in viability reduction
compared to the live control.
Additional file 2: Flow chart outlining the screening process of the
55 drugs tested.
Additional file 3: Single-agent drug toxicity pre-screen (20 μM) with
PC3-TR cell line. Drugs found to induce a decrease in cell viability
greater than 30% were retested at an alternate drug concentration of 10
μM (drugs circled). Drugs were incubated with the cells for a 24-hour
period after which an MTT analysis was performed.
Additional file 4: Dose response for gemcitabine in malignant cell
lines. (a) PC3-TR, (b) PC3 human prostate cancer cells, and (c) Panc-1
pancreatic cancer cells. Single-agent treatments are shown as “dark grey
diamonds” and combination treatments with 10 ng/mL of TRAIL are
shown as “light grey squares”. Asterisks (*) and (**) indicate p-values <
0.05 and < 0.01, respectively. (d) molecular structure of gemcitabine.
Arrows indicate the concentrations at which the enhancement in
viability reduction is the greatest. Data are presented on a logarithmic
scale and the lines connecting data points are for visualization only.
Additional file 5: Dose response for thioTEPA in malignant cell
lines. (a) PC3-TR, (b) PC3 human prostate cancer cells, and (c) Panc-1
pancreatic cancer cells. Single-agent treatments are shown as “dark grey
diamonds” and combination treatments with 10 ng/mL of TRAIL are
shown as “light grey squares”. Asterisks (*) and (**) indicate p-values <
0.05 and < 0.01, respectively. (d) molecular structure of thioTEPA. Data
are presented on a logarithmic scale and the lines connecting data
points are for visualization only.
Additional file 6: Microscopy images of mithramycin treated PC3-TR
cells. Left panels are phase contrast images and right panels are
fluorescence images visualized with an annexin V and propidium iodide
stain. Apoptotic cells exhibit green fluorescence only. Dead cells can
exhibit either lone red fluorescence or red and green fluorescence
simultaneously. Live cells are non-fluorescent. Arrows identify apoptotic
cells.
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